Aidea Pharma(SH:688488) Xin Lang Cai Jing·2025-09-18 02:09Group 1 - The core viewpoint of the news is that Eddy Pharmaceutical has seen a 5% increase in stock price, reaching 15.95 CNY per share, with a total market capitalization of 6.711 billion CNY [1] - Eddy Pharmaceutical, established on December 15, 2009, and listed on July 20, 2020, focuses on the exploration, research, and sales of innovative chemical drugs and human-derived protein products [1] - The revenue composition of Eddy Pharmaceutical includes human-derived proteins at 41.11%, new drugs at 35.69%, diagnostic equipment and reagents at 13.62%, generic drugs at 9.47%, and other supplementary products at 0.11% [1] Group 2 - According to data, the Guotou Ruijin Fund has a significant holding in Eddy Pharmaceutical, with the Guotou Ruijin Specialized and New Quantitative Stock Selection Mixed A Fund (015842) holding 76,300 shares, accounting for 1.39% of the fund's net value [2] - The Guotou Ruijin Specialized and New Quantitative Stock Selection Mixed A Fund has achieved a year-to-date return of 51.3% and a one-year return of 113.06%, ranking 894 out of 8172 and 352 out of 7980 in its category, respectively [2] - The fund manager, Zhao Jian, has been in position for nearly 12 years, with the fund's total asset size at 3.848 billion CNY and a best return of 172.91% during his tenure [3]